Business Context and Reporting Period
This Form 8-K Current Report was filed by Editas Medicine, Inc. on May 30, 2017. The filing addresses corporate governance changes, specifically the appointment of a new director to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel and compensation arrangements rather than financial performance.
Material Changes
- Board Expansion: The Board of Directors increased its size by one member.
- New Appointment: Andrew Hirsch was appointed as a director, effective immediately, designated as a Class II director.
- Committee Roles: Mr. Hirsch was named to the Audit Committee and appointed as its chairman, effective immediately.
Guidance, Outlook, and Compensation
There is no financial guidance or outlook provided in this filing. The document details the compensatory arrangements for the new director:
- Cash Compensation: $35,000 annual cash compensation as a Board member.
- Committee Fee: $7,500 annual fee for serving as chair of the Audit Committee.
- Equity Grant: An option to purchase 23,076 shares of common stock at the closing price on the date of appointment. The option vests in three equal installments over three years, contingent on continued service.
- Expenses: Reimbursement for reasonable travel and other expenses.
Investor Verification Checklist
- Verify the vesting schedule and exercise price of the 23,076 stock options granted to Andrew Hirsch.
- Confirm the total number of Board members following this appointment.
- Review the impact of the new Audit Committee chair on the company's financial oversight structure.
- Check subsequent filings for any changes to the Board composition or Mr. Hirsch's tenure.